The Modern Financial Terminal

Subscribe for $2

Trusted by leading companies and financial institutions

BlackRock logoAllianz logoGoogle logoAnthropic logoBloomberg logoRevolut logoNASDAQ logoCoinbase logo
BlackRock logoAllianz logoGoogle logoAnthropic logoBloomberg logoRevolut logoNASDAQ logoCoinbase logo

Boston Scientific Stock BSX

Price

91.82
Today +/-
+0.05
Today %
+0.07 %
P

Boston Scientific stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Boston Scientific stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Boston Scientific stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Boston Scientific stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Boston Scientific's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Boston Scientific Stock Price History

DateBoston Scientific Price
91.82 undefined
91.76 undefined
91.52 undefined
93.55 undefined
92.36 undefined
93.98 undefined
93.68 undefined
93.77 undefined
92.27 undefined
91.31 undefined
91.73 undefined
91.52 undefined
88.42 undefined
88.09 undefined
90.01 undefined
93.76 undefined
94.16 undefined
95.92 undefined
97.66 undefined
98.40 undefined
99.02 undefined
97.81 undefined
95.50 undefined

Boston Scientific Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Boston Scientific, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Boston Scientific from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Boston Scientific’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Boston Scientific. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Boston Scientific’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Boston Scientific’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Boston Scientific’s growth potential.

Boston Scientific Revenue, EBIT and net profit per share

DateBoston Scientific RevenueBoston Scientific EBITBoston Scientific Net Income
2030e33.64 B undefined10.15 B undefined8.56 B undefined
2029e30.35 B undefined9.02 B undefined7.51 B undefined
2028e27.38 B undefined8.02 B undefined6.64 B undefined
2027e25.05 B undefined7.08 B undefined5.89 B undefined
2026e22.59 B undefined6.32 B undefined5.19 B undefined
2025e20.27 B undefined5.61 B undefined4.54 B undefined
202416.75 B undefined3.06 B undefined1.85 B undefined
202314.24 B undefined2.43 B undefined1.57 B undefined
202212.68 B undefined2.07 B undefined642 M undefined
202111.89 B undefined2.11 B undefined985 M undefined
20209.91 B undefined902 M undefined-115 M undefined
201910.74 B undefined1.82 B undefined4.7 B undefined
20189.82 B undefined1.74 B undefined1.67 B undefined
20179.05 B undefined1.67 B undefined104 M undefined
20168.39 B undefined1.34 B undefined347 M undefined
20157.48 B undefined924 M undefined-239 M undefined
20147.38 B undefined1.04 B undefined-119 M undefined
20137.14 B undefined903 M undefined-121 M undefined
20127.25 B undefined961 M undefined-4.07 B undefined
20117.62 B undefined1.02 B undefined441 M undefined
20107.81 B undefined993 M undefined-1.07 B undefined
20098.19 B undefined1.25 B undefined-1.03 B undefined
20088.05 B undefined1.27 B undefined-2.04 B undefined
20078.36 B undefined1.19 B undefined-495 M undefined
20067.82 B undefined1.23 B undefined-3.58 B undefined
20056.28 B undefined2.02 B undefined628 M undefined

Boston Scientific Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
SHARES (B)
DOCUMENTS
1989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
0.120.160.230.320.730.891.191.551.832.232.842.662.672.923.485.626.287.828.368.058.197.817.627.257.147.387.488.399.059.8210.749.9111.8912.6814.2416.7520.2722.5925.0527.3830.3533.64
-37.3945.5736.96132.3821.3134.0130.3417.9922.0227.27-6.260.349.2019.0861.8011.7224.486.85-3.671.71-4.67-2.36-4.89-1.463.321.3112.167.898.579.28-7.6619.926.6812.2917.6121.0611.4310.869.3210.8410.83
55.6562.0364.3562.8666.1265.6568.9971.3169.0265.7063.6967.3864.3168.9670.8073.5674.3368.8369.5666.8166.2164.3463.2565.6067.6068.8870.4270.5671.0971.1370.6765.2469.0469.0069.6568.7256.7750.9445.9542.0337.9234.21
0.060.10.150.20.480.580.821.111.261.471.811.81.722.012.464.144.675.385.815.385.425.024.824.764.835.085.275.926.436.997.596.478.218.759.9211.51000000
0.010.020.040.060.120.14-0.020.170.11-0.260.370.37-0.050.370.471.060.63-3.58-0.5-2.04-1.03-1.070.44-4.07-0.12-0.12-0.240.350.11.674.7-0.120.990.641.571.854.545.195.866.647.518.56
-283.3378.2636.59116.0711.57-113.33-1,027.78-34.13-340.00-240.530.54-114.48-790.7426.54125.00-40.87-669.59-86.16311.31-49.663.90-141.41-1,022.45-97.03-1.65100.84-245.19-70.031,506.73181.27-102.45-956.52-34.82144.5518.03145.1714.2912.9213.2713.0114.11
0.380.380.380.40.680.70.760.80.80.780.820.820.80.830.850.860.841.271.491.51.511.521.521.411.341.321.341.381.391.41.411.421.431.441.461.49000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Boston Scientific Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Boston Scientific is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (B)
OTHER REC. (M)
INVENTORIES (B)
OTHER CURRENT LIAB. (B)
CURRENT ASSETS (B)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (B)
GOODWILL (B)
OTHER NON-CURRENT ASSETS (B)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (B)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (B)
OTHER SHORT-TERM LIAB. (B)
SHORT-TERM DEBTS (B)
LONG-TERM DEBT PORTION (B)
SHORT-TERM REC. (B)
LONG-T. LIAB. (B)
DEFERRED TAXES (B)
OTHER LIAB. (B)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                                     
00.010.140.10.340.160.120.080.080.080.060.190.260.751.640.851.671.451.640.860.210.270.210.220.590.320.20.190.150.221.731.930.930.870.41
0.030.040.050.060.140.210.320.370.540.450.360.370.440.540.90.931.391.51.41.381.321.251.221.311.181.281.471.551.611.831.531.781.972.232.56
0.35.260.5400000000000000000000000000000000
0.030.040.040.040.10.150.240.390.460.380.350.30.240.280.360.420.680.730.850.890.890.930.880.90.951.020.961.081.171.581.351.611.872.482.81
00.010.010.010.070.050.140.180.190.160.220.250.270.310.390.432.292.261.561.471.190.660.710.590.890.860.621.011.081.082.08110.941.14
0.060.090.240.220.660.580.821.021.271.060.991.111.211.883.292.636.035.945.454.63.623.113.023.013.613.473.243.8244.76.696.325.766.516.92
0.030.040.050.080.220.260.360.50.680.60.570.590.640.740.871.011.641.721.731.721.71.671.561.551.511.491.631.71.782.422.542.692.833.33.74
000000066.2434.065599154210558529594596317000000000000918412407413555
00000000000000000000000000000000000
00000.080.140.20.210.940.890.851.151.21.191.631.88.387.967.246.676.346.476.295.955.616.195.885.846.377.895.926.125.966.68
0000000.120.10.880.840.820.921.171.281.711.941415.112.4211.9410.199.765.975.695.96.476.6877.9110.189.9511.9912.9214.3917.09
0.010.010.010.030.040.140.090.030.10.130.10.060.030.060.140.230.230.160.290.250.290.280.310.370.410.510.670.690.935.394.764.74.654.524.4
0.040.050.060.110.330.530.770.92.632.522.442.873.243.824.885.5724.8525.2621.6920.5818.5118.1914.1313.5613.4214.6614.8615.221725.8724.0825.9126.7128.6232.48
0.10.140.30.320.991.111.591.923.893.573.433.974.455.78.178.230.8831.227.1425.1822.1321.2917.1516.5717.0218.1318.119.042130.5730.7832.2332.4735.1439.4
                                                                     
0.940.941.021.021.671.791.961.963.94444488815151515151515161616161616161717171717
0.020.020.140.130.310.390.440.430.511.211.211.231.251.231.631.6615.7915.7915.9416.0916.2316.3516.4316.5816.716.8617.0117.1617.3517.5619.7319.9920.2920.6521.06
0.030.070.110.170.450.420.570.680.380.751.121.031.391.792.793.41-0.17-0.69-2.73-3.76-4.82-4.38-8.45-8.57-8.69-8.93-8.58-8.39-6.95-2.25-2.38-1.39-0.750.822.67
0.410.6-0.27-1.31.34-5.91-13.11-75.98-72.29-123-130-97-125-99-88-103-17-29-53-43-129-138-33106144887-573427020626226850275
00000018.8917.421.4971725-250226161600000000-6-10000000
0.050.090.250.310.760.81.021.050.821.852.222.192.522.974.35515.6315.113.1712.311.311.857.968.138.178.048.458.7310.4415.5917.5818.8719.8221.5324.02
5.56.766.4610.6932.9143.0666.8898.88108.69267546678108105204139239212184203232246262209447530349542513794862942960
0.010.010.010.010.050.060.150.160.250.290.350.420.640.60.91.121.121.211.171.161.191.21.181.261.261.21.251.281.531.711.762.241.992.522.68
00.010.010.010.080.120.030.090.240.080.140.130.130.170.370.091.31.651.821.650.740.40.350.310.931.021.832.041.121.21.390.980.930.940.98
0.0200.020.030.090.060.240.451.030.60.260.230.090.550.730.160000000000000000000
000000000000000.500.010.26000.50000.400.061.82.251.420.010.260.020.531.78
0.030.030.040.060.260.280.480.791.621.060.820.830.921.392.611.482.633.253.233.022.611.811.771.822.852.433.595.655.264.873.684.273.84.936.4
0.020.020.010.010.03000.051.360.690.570.970.851.171.141.868.97.936.745.924.934.264.254.243.845.675.423.824.88.599.138.88.928.578.97
0000000.060.060000.040.10.150.260.262.572.282.261.881.641.871.711.41.210.740.020.190.330.60.330.310.140.130.16
0000.0100.050.050.070.090.110.10.110.110.120.140.311.492.631.732.061.652.012.552.572.672.972.342.371.882.642.312.222.031.971.87
0.020.020.010.020.030.050.110.171.450.790.671.131.061.441.542.4412.9512.8510.739.858.228.138.518.217.729.387.786.387.0111.8211.7711.3311.0910.6710.99
0.050.050.050.080.290.340.590.973.071.851.491.961.982.844.153.9115.5816.113.9712.8810.839.9410.2810.0310.5711.8111.3612.0312.2716.6915.4515.6114.915.6117.39
0.10.140.30.381.051.141.612.023.893.73.714.154.55.818.498.9131.2231.227.1425.1822.1321.7818.2518.1618.7419.8519.8120.7622.7232.2833.0334.4834.7237.1441.41
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Boston Scientific provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Boston Scientific's financial health and stability.

Assets

Boston Scientific's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Boston Scientific must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Boston Scientific after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Boston Scientific's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)
DEPRECIATION (B)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (B)
PAID INTEREST (M)
PAID TAXES (B)
NET CASH FLOW FROM OPERATING ACTIVITIES (B)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (B)
NET CHANGE IN EQUITY (B)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
19891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.010.020.040.060.080.14-0.020.170.11-0.260.370.37-0.050.370.471.060.63-3.58-0.5-2.04-1.03-1.070.44-4.07-0.12-0.12-0.240.350.11.674.7-0.081.040.71.59
00000.030.040.040.070.090.130.180.180.230.160.20.280.310.730.920.860.830.820.720.680.690.730.770.820.840.891.011.121.091.141.2
0000-38-22-8-11-52-151-2928142-31304-420-386-334-64-11046-166-223-397-532-305245-87-4,301-82-124-63-1
-1-7-15-1945-51-48-205-124-9621219225-27-4174-40335847-77922-1,362-24429721498932620667-2,162-28441-351-1,006-771
00000-00.060.130.060.680.04-0.010.280.090.190.360.364.760.972.940.312.20.184.640.660.170.470.240.290.130.870.680.410.980.72
6532346131965117695943526187383543414364328277255329221283233235262449359338450259
00.010.020.040.080.090.080.090.090.110.090.050.110.040.030.070.350.20.480.420.05-0.290.140.10.070.070.080.090.041.040.240.210.30.660.51
0.010.020.030.040.110.10.030.140.080.290.780.740.490.740.791.80.91.850.931.220.840.331.011.281.111.270.691.181.430.311.841.511.871.532.5
-7-3-7-10-106-99-199-228-267-177-83-126-205-314-513-546-549-439-486-418-362-278-315-248-289-285-513-508-450-488-610-522-554-588-711
-7-5-10-50-137-50-182-401-251-2,225-185-107-800-485-871-1,622-551-9,312-474324-793-480769-579-475-745-2,186-887-1,010-1,921-5,041-411-1,597-2,011-2,574
0-0-0-0.04-0.030.050.02-0.170.02-2.05-0.10.02-0.6-0.17-0.36-1.08-0-8.870.010.74-0.43-0.21.08-0.33-0.19-0.46-1.67-0.38-0.56-1.43-4.430.11-1.04-1.42-1.86
00000000000000000000000000000000000
0-0.01-0.01-0.010.030.04-0.040.180.251.88-1.12-0.450.4-0.280.790.58-0.316.89-0.75-1.43-0.85-0.53-1.25-0.02-0.0101.39-0.190.121.412.79-10-0.17-0
0000.12-0.060.030.050.01-0.090.070.53-0.190.040.11-0.31-0.14-0.641.550.070.070.030.03-0.47-0.58-0.43-0.070.110.110.090.10.121.530.110.140.18
0-0.01-0.010.1-0.020.080.010.20.161.94-0.59-0.640.44-0.180.490.44-0.958.44-0.68-1.35-0.82-0.5-1.72-0.76-0.62-0.151.28-0.210.111.432.970.29-0.1-0.550.01
000110000-5-12014-3-1624000-166-188-85-223-127-98-7456-206-150-464-145
000-20000000000000000000000000000-28-55-55-28
000.010.09-0.050.12-0.14-0.06-0.010.01-0.01-0.010.130.080.410.63-0.610.98-0.220.19-0.78-0.650.05-0.060.010.37-0.220.090.53-0.19-0.221.390.17-1.04-0.07
-0.215.622.332.13.4-3-167.4-86.8-186.51166936132854222741,2583541,406448798473476931,032821984178674976-1791,2269861,3179381,792
00000000000000000000000000000000000

Boston Scientific stock margins

The Boston Scientific margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Boston Scientific. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Boston Scientific.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Boston Scientific's sales revenue. A higher gross margin percentage indicates that the Boston Scientific retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Boston Scientific's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Boston Scientific's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Boston Scientific's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Boston Scientific. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Boston Scientific's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Boston Scientific Margin History

Boston Scientific Gross marginBoston Scientific Profit marginBoston Scientific EBIT marginBoston Scientific Profit margin
2030e68.72 %30.16 %25.46 %
2029e68.72 %29.72 %24.73 %
2028e68.72 %29.3 %24.26 %
2027e68.72 %28.28 %23.51 %
2026e68.72 %27.98 %22.98 %
2025e68.72 %27.68 %22.42 %
202468.72 %18.25 %11.06 %
202369.65 %17.05 %11.03 %
202269 %16.33 %5.06 %
202169.04 %17.77 %8.29 %
202065.24 %9.1 %-1.16 %
201970.67 %16.96 %43.78 %
201871.13 %17.7 %17.01 %
201771.09 %18.45 %1.15 %
201670.56 %15.98 %4.14 %
201570.42 %12.36 %-3.2 %
201468.88 %14.02 %-1.61 %
201367.6 %12.64 %-1.69 %
201265.6 %13.26 %-56.12 %
201163.25 %13.33 %5.79 %
201064.34 %12.72 %-13.64 %
200966.21 %15.32 %-12.52 %
200866.81 %15.79 %-25.29 %
200769.56 %14.28 %-5.92 %
200668.83 %15.68 %-45.74 %
200574.33 %32.21 %10 %

Boston Scientific Stock Sales Revenue, EBIT, Earnings per Share

The Boston Scientific earnings per share therefore indicates how much revenue Boston Scientific has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Boston Scientific earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Boston Scientific's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Boston Scientific’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Boston Scientific's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Boston Scientific Revenue, EBIT and net profit per share

DateBoston Scientific Sales per ShareBoston Scientific EBIT per shareBoston Scientific Earnings per Share
2030e22.69 undefined6.83 undefined5.78 undefined
2029e20.47 undefined6.07 undefined5.06 undefined
2028e18.47 undefined5.4 undefined4.48 undefined
2027e16.9 undefined4.77 undefined3.97 undefined
2026e15.24 undefined4.25 undefined3.5 undefined
2025e13.68 undefined3.78 undefined3.07 undefined
202411.27 undefined2.06 undefined1.25 undefined
20239.73 undefined1.66 undefined1.07 undefined
20228.81 undefined1.44 undefined0.45 undefined
20218.29 undefined1.47 undefined0.69 undefined
20207 undefined0.64 undefined-0.08 undefined
20197.61 undefined1.29 undefined3.33 undefined
20187.01 undefined1.24 undefined1.19 undefined
20176.5 undefined1.2 undefined0.07 undefined
20166.09 undefined0.97 undefined0.25 undefined
20155.57 undefined0.69 undefined-0.18 undefined
20145.57 undefined0.78 undefined-0.09 undefined
20135.33 undefined0.67 undefined-0.09 undefined
20125.15 undefined0.68 undefined-2.89 undefined
20115.02 undefined0.67 undefined0.29 undefined
20105.14 undefined0.65 undefined-0.7 undefined
20095.43 undefined0.83 undefined-0.68 undefined
20085.37 undefined0.85 undefined-1.36 undefined
20075.62 undefined0.8 undefined-0.33 undefined
20066.14 undefined0.96 undefined-2.81 undefined
20057.5 undefined2.42 undefined0.75 undefined

Boston Scientific business model

Boston Scientific Corp. is a global medical technology company specializing in the development and manufacturing of innovative solutions for medical challenges and needs. The company was founded in 1979 and has since been dedicated to meeting the individual needs of patients and medical professionals with innovative products. The history of Boston Scientific began in the 1960s when French engineer Jean-Marc Simon started developing pacemakers at the University of Minnesota. In 1969, Medtronic acquired Simon's pacemaker development, leading to the founding of Boston Scientific. From the beginning, the company focused on the production of cardiovascular implants, including pacemakers, implanted defibrillators, and stents. In the following years, the company achieved continued growth through acquisitions of competitors and advancements in research and development, particularly in the field of minimally invasive procedures. Today, Boston Scientific is a globally leading provider of innovative medical devices and solutions used in various areas of healthcare. Boston Scientific's business model is based on meeting the needs of patients, medical professionals, and healthcare policymakers in order to improve healthcare. The company works closely with doctors, hospitals, nursing facilities, and research institutions to continuously develop innovative solutions for various diseases and conditions. Boston Scientific has five business segments: Cardiovascular Systems, Interventional Oncology and Neuromodulation, Urology and Women's Health, Medical Oncology, and Endoscopy. The Cardiovascular Systems segment includes products and solutions for cardiovascular surgery, including pacemakers, implanted defibrillators, and catheters. The company is also involved in endovascular surgery, offering innovative stent and catheter systems for the treatment of aneurysms and arterial occlusive disease. The Interventional Oncology and Neuromodulation segment includes solutions for the minimally invasive treatment of cancer and chronic pain through catheter and implant systems. For example, Boston Scientific offers intensity-controlled radiofrequency ablation and neuromodulation procedures. The Urology and Women's Health segment includes products for the treatment and diagnosis of urogenital system disorders, including incontinence, urinary incontinence, and genital diseases. Boston Scientific offers innovative solutions for women, such as the treatment of urinary incontinence or the removal of uterine fibroids. The Medical Oncology segment includes products for the diagnosis and treatment of cancer, including in vitro diagnostics and novel treatments such as chemotherapy delivery technology. The Endoscopy segment includes endoscopic solutions, including the diagnosis and therapy of digestive tract, chest, and lung disorders. Boston Scientific's product portfolio is diverse and includes numerous innovative medical devices and systems designed to meet the needs of patients and medical professionals. Some of the notable products of the company include: - The Implantable Cardioverter-Defibrillator (ICD) is an innovative device that can treat heart rhythm disorders through the use of a remote control. - Drug-Eluting Stents are stents that deliver medication directly at the site of narrowing, promoting blood flow and helping to keep the artery open. - The Synergy is a top-of-the-line stent that has both a lower mortality rate and a higher success rate than conventional stents. - The Venus-EP Steerable Sheath is an advanced catheter that allows physicians unique navigation within the heart chambers. - The Precision is a catheter that sends impulses to the heart for the diagnosis and treatment of atrial fibrillation. - The Transcend is a pacemaker that combines traditional pacemaker function with a sensor that actively supports the patient during physical activity. - The Symphion is an innovative system for laparoscopic surgery that enables minimally invasive surgical procedures in women. In conclusion, Boston Scientific Corp. is a globally leading provider of innovative medical devices and solutions that run like a common thread through its various business segments. With a significant focus on research and development, the company offers a wide range of products to ensure that patients worldwide have access to innovative medical care. Through pioneering innovations, the development of new technologies, and collaboration with medical professionals, Boston Scientific will continue to defend its position as a leading provider of medical solutions worldwide. Boston Scientific is one of the most popular companies on Eulerpool.com.

Boston Scientific SWOT Analysis

Helpful
Harmful
Internal

Strengths

Boston Scientific Corp has a strong portfolio of innovative medical devices and technologies that cater to a wide range of medical specialties.

The company has a global presence and operates in over 130 countries, providing access to a large customer base and potential for market expansion.

Boston Scientific Corp has a solid reputation for delivering high-quality products and services, leading to strong customer loyalty and trust.

Weaknesses

One of the weaknesses for Boston Scientific Corp is its dependence on third-party suppliers for certain critical components, which makes the company vulnerable to supply chain disruptions.

The company has faced challenges related to regulatory compliance, which can impact its ability to introduce new products and comply with changing market requirements.

Boston Scientific Corp operates in a highly competitive market, which puts pressure on pricing and profit margins.

External

Opportunities

The growing global healthcare market presents opportunities for Boston Scientific Corp to expand its customer base and increase sales.

Advancements in medical technology and increased adoption of minimally invasive procedures create opportunities for the company to develop and introduce new innovative products.

Expansion into emerging markets, such as Asia and Latin America, offers the potential for significant revenue growth for Boston Scientific Corp.

Threats

Intense competition from other medical device companies poses a threat to Boston Scientific Corp's market share and profitability.

Changes in healthcare regulations and policies can impact the pricing and reimbursement of medical devices, posing challenges to the company's financial performance.

Fluctuating currency exchange rates can affect Boston Scientific Corp's international operations and profitability.

Boston Scientific Revenue by Segment

  • 3 Years

  • 5 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Boston Scientific Revenue by Segment

Segmente20222021202020192016201520142010
Global Cardiology Reporting Unit5.93 B USD-------
Global Endoscopy (Endo) Reporting Unit2.22 B USD--1.89 B USD----
Global Peripheral Interventions (PI) Reporting Unit1.9 B USD--1.39 B USD----
Global Urology and Pelvic Health Reporting Unit1.77 B USD--1.41 B USD----
Global Interventional Cardiology (IC) Reporting Unit---2.82 B USD----
Interventional Cardiology Therapies2.23 B USD-------
Cardiac Rhythm Management2.1 B USD-------
Global CRM Reporting Unit---1.94 B USD----
Global Neuromodulation (NM) Reporting Unit917 M USD--873 M USD----
Watchman1.02 B USD-------
Electrophysiology (EP)585 M USD-------
Global Electrophysiology (EP) Reporting Unit---329 M USD----
Specialty Pharmaceuticals-13 M USD------
BTG Spec Pharma---11 M USD----
Other--------

  • 3 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Boston Scientific Revenue by Segment

Segmente20222021202020192016201520142010
Other-60 M USD-------

  • 3 Years

  • 5 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Boston Scientific Revenue by Segment

Segmente20222021202020192016201520142010
Global Interventional Cardiology (IC) Reporting Unit-3.04 B USD2.3 B USD-----
Global Endoscopy (Endo) Reporting Unit-2.14 B USD1.78 B USD-----
Global CRM Reporting Unit-2.02 B USD1.7 B USD-----
Global Peripheral Interventions (PI) Reporting Unit-1.82 B USD1.58 B USD-----
Global Urology and Pelvic Health Reporting Unit-1.58 B USD1.29 B USD-----
Global Neuromodulation (NM) Reporting Unit-909 M USD761 M USD-----
Global Electrophysiology (EP) Reporting Unit-365 M USD287 M USD-----
Specialty Pharmaceuticals--219 M USD-----

  • 3 Years

  • 5 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Boston Scientific Revenue by Segment

Segmente20222021202020192016201520142010
BSX Reportable Segments-11.88 B USD9.69 B USD-----
Cardiovascular7.83 B USD-------
MedSurg4.91 B USD-------

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Boston Scientific Revenue by Segment

Segmente20222021202020192016201520142010
Cardiovascular-4.86 B USD3.88 B USD----3.27 B USD
BSX Reportable Segments---10.65 B USD----
MedSurg-3.72 B USD3.07 B USD3.31 B USD----
Rhythm and Neuro-3.29 B USD2.75 B USD3.14 B USD----
Global Interventional Cardiology (IC) Reporting Unit----2.52 B USD2.24 B USD2.09 B USD-
Global Endoscopy (Endo) Reporting Unit----1.57 B USD1.42 B USD1.34 B USD-
Global Peripheral Interventions (PI) Reporting Unit----1.09 B USD975 M USD861 M USD-
Global Urology (Uro) Reporting Unit----1.07 B USD735 M USD542 M USD-
Cardiac Rhythm Management-------2.18 B USD
Global Neuromodulation (NM) Reporting Unit----574 M USD512 M USD474 M USD-
Endoscopy-------1.08 B USD
Urology Women's/Health-------481 M USD
Neurovascular-------340 M USD
Neuromodulation-------304 M USD
Electrophysiology-------147 M USD

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Boston Scientific Revenue by Segment

Segmente20222021202020192016201520142010
Cardiovascular---4.21 B USD3.62 B USD3.22 B USD2.95 B USD-
MedSurg----3.2 B USD2.67 B USD2.36 B USD-
Rhythm Management----2.26 B USD2.18 B USD2.15 B USD-
Global CRM Reporting Unit----1.99 B USD1.93 B USD1.92 B USD-
Global Electrophysiology (EP) Reporting Unit----261 M USD248 M USD228 M USD-
Other Segments---81 M USD----

Boston Scientific Revenue by Region

  • 3 Years

  • 5 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Boston Scientific Revenue by Segment

DateAPACAsia Pacificcountry_US excluding Other Net SalesEMEAEmerging MarketsLatin America and CanadaOther CountriesU.SUnited States
20232.4 B USD-8.43 B USD2.86 B USD2.31 B USD560 M USD5.82 B USD8.43 B USD-
20222.12 B USD-7.63 B USD2.53 B USD1.72 B USD469 M USD5.11 B USD-7.63 B USD
20212.07 B USD--2.52 B USD1.43 B USD386 M USD4.98 B USD-6.9 B USD
20201.78 B USD--2.1 B USD1.09 B USD307 M USD4.21 B USD-5.51 B USD
2019-1.9 B USD-2.26 B USD1.25 B USD395 M USD4.57 B USD-6.1 B USD
2018-1.73 B USD-2.18 B USD1.07 B USD383 M USD4.29 B USD-5.54 B USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Boston Scientific Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Boston Scientific historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Boston Scientific shares outstanding

The number of shares was Boston Scientific in 2025 — This indicates how many shares 1.486 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Boston Scientific earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Boston Scientific's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Boston Scientific’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Boston Scientific's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Boston Scientific stock splits

In Boston Scientific's history, there have been no stock splits.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Boston Scientific.

Boston Scientific Earnings Calls

October 22, 2025
Boston Scientific Corporation (BSX) Q3 2025 Earnings Call Transcript
PDF Audio
July 23, 2025
Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript
Audio
April 23, 2025
Boston Scientific Corporation (BSX) Q1 2025 Earnings Call Transcript
Audio
February 5, 2025
Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript
Audio
November 2, 2024
Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript
Audio
October 23, 2024
Boston Scientific Corporation (BSX) Q3 2024 Earnings Call Transcript
Audio
July 24, 2024
Boston Scientific Corporation (BSX) Q2 2024 Earnings Call Transcript
PDF Audio
April 24, 2024
Boston Scientific Corporation (BSX) Q1 2024 Earnings Call Transcript
PDF Audio
January 31, 2024
Boston Scientific Corporation (BSX) Q4 2023 Earnings Call Transcript
Audio
October 26, 2023
Boston Scientific Corporation (BSX) Q3 2023 Earnings Call Transcript
PDF Audio
1
2

Boston Scientific Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
2/4/20260.79 5.33 B 2025 Q4
4/24/20240.52 3.7 B 2024 Q1
1/30/20240.52 3.63 B 2023 Q4
7/25/20230.49 3.47 B 2023 Q2
4/25/20230.45 3.22 B 2023 Q1
1/31/20230.48 3.29 B 2022 Q4
10/26/20220.45 3.18 B 2022 Q3
7/27/20220.43 3.26 B 2022 Q2
4/27/20220.39 3 B 2022 Q1
2/2/20220.44 3.16 B 2021 Q4
1
2
3
4
5
...
10

Eulerpool ESG Scorecard© for the Boston Scientific stock

Eulerpool World ESG Rating (EESG©)

71/ 100

🌱 Environment

56

👫 Social

94

🏛️ Governance

63

Environment

Scope 1 - Direct Emissions
87,567
Scope 2 - Indirect emissions from purchased energy
112,861
Scope 3 - Indirect emissions within the value chain
2,035,890
Total CO₂ emissions
200,429
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees49.9
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees61
White Management Share77.8
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Boston Scientific shareholders

%
Name
Stocks
Change
Date
9.20610 % The Vanguard Group, Inc.136,474,9142,527,437
6.71008 % Fidelity Management & Research Company LLC99,472,942-17,981,331
5.27410 % BlackRock Institutional Trust Company, N.A.78,185,425380,396
4.39761 % State Street Investment Management (US)65,191,864713,379
2.33822 % PRIMECAP Management Company34,662,722-1,834,224
2.20241 % Wellington Management Company, LLP32,649,465-548,377
2.18727 % Geode Capital Management, L.L.C.32,424,982622,602
1.92418 % Capital World Investors28,524,768-33,953
1.48758 % Managed Account Advisors LLC22,052,495765,606
1.35449 % The Bollard Group, LLC20,079,443-411,383
1
2
3
4
5
...
10

Boston Scientific Executives and Management Board

Mr. Michael Mahoney

(60)
Boston Scientific Chairman of the Board, President, Chief Executive Officer (since 2011)
Compensation 21.42 M

Mr. Joseph Fitzgerald

(61)
Boston Scientific Executive Vice President, Group President - Cardiology
Compensation 6.34 M

Mr. Arthur Butcher

(54)
Boston Scientific Executive Vice President, Group President, MedSurg and Asia Pacific
Compensation 5.01 M

Mr. Jeffrey Mirviss

(59)
Boston Scientific Executive Vice President and President - Peripheral Interventions
Compensation 4.03 M

Mr. Edward Ludwig

(73)
Boston Scientific Lead Independent Director
Compensation 376,667
1
2
3
4

Boston Scientific Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Zinc Media Group Stock
Zinc Media Group
SupplierCustomer 0,02-0,40-0,070,250,43
Lisi S.A. Stock
Lisi S.A.
SupplierCustomer 0,22
Japan Lifeline Co., Ltd. Stock
Japan Lifeline Co., Ltd.
SupplierCustomer 0,10
Nolato AB (publ) Stock
Nolato AB (publ)
SupplierCustomer -0,59-0,81-0,37
PTC Stock
PTC
SupplierCustomer0,760,39-0,47-0,370,510,36
SurModics Stock
SurModics
SupplierCustomer0,680,440,590,070,810,60
Integer Holdings Stock
Integer Holdings
SupplierCustomer0,670,390,770,540,740,64
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,620,100,380,590,790,49
Tufin Software Technologies Ltd. Stock
Tufin Software Technologies Ltd.
SupplierCustomer0,530,420,550,28-0,130,37
Asahi Intecc Stock
Asahi Intecc
SupplierCustomer0,480,330,650,20-0,67-0,10
1
2
3

Most common questions regarding Boston Scientific

What values and corporate philosophy does Boston Scientific represent?

Boston Scientific Corp represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy focused on improving patients' lives, the company is committed to developing and delivering innovative medical solutions. Boston Scientific Corp's dedication to collaboration extends to its partnerships with healthcare professionals and institutions, helping to address unmet needs and improve patient outcomes. By prioritizing patient-centric care, the company ensures that its products and services are designed to provide effective and meaningful treatments. Boston Scientific Corp's continued commitment to innovation and collaboration underscores its mission to transform lives through medical advancements in a rapidly evolving healthcare landscape.

In which countries and regions is Boston Scientific primarily present?

Boston Scientific Corp is primarily present in several countries and regions worldwide. The company has a strong global presence, with significant operations in the United States, Europe, Asia-Pacific, Latin America, and the Middle East. Its diverse market reach spans across more than 130 countries, enabling Boston Scientific Corp to provide innovative medical solutions and technologies to a vast range of patients and healthcare professionals worldwide.

What significant milestones has the company Boston Scientific achieved?

Boston Scientific Corp has achieved significant milestones throughout its history. Some notable achievements include the development of the Taxus Express, a groundbreaking drug-eluting stent that revolutionized the treatment of coronary artery disease. Additionally, the acquisition of Guidant Corporation strengthened Boston Scientific's position in the field of cardiac rhythm management. The company's innovative products, such as the Watchman Left Atrial Appendage Closure device, have provided improved treatment options for patients with atrial fibrillation. Boston Scientific Corp continues to innovate and make advancements in medical technologies, helping to improve patient outcomes worldwide.

What is the history and background of the company Boston Scientific?

Boston Scientific Corp is a renowned medical technology company based in Marlborough, Massachusetts. Established in 1979, it has become a global leader in the development, manufacturing, and marketing of innovative medical devices. With a focus on advancing patient care, Boston Scientific Corp offers a wide range of products for various medical specialties, including interventional cardiology, urology, endoscopy, and neuromodulation. The company's history showcases its commitment to medical breakthroughs and improving the lives of patients worldwide. Boston Scientific Corp's dedication to cutting-edge technology and strategic acquisitions has allowed it to maintain a prominent position in the healthcare industry.

Who are the main competitors of Boston Scientific in the market?

The main competitors of Boston Scientific Corp in the market include Medtronic, Johnson & Johnson, Abbott Laboratories, and Edwards Lifesciences.

In which industries is Boston Scientific primarily active?

Boston Scientific Corp is primarily active in the medical equipment and supplies industry.

What is the business model of Boston Scientific?

Boston Scientific Corp is a global medical technology company. Its business model revolves around developing innovative medical solutions that enhance patient care and healthcare outcomes. Boston Scientific Corp manufactures and markets a broad range of medical devices used in various specialties, such as cardiology, urology, endoscopy, and neuromodulation. The company's commitment to research and development enables it to introduce advanced technologies and therapies that address unmet clinical needs. Boston Scientific Corp also focuses on collaborations and partnerships to expand its product portfolio, improve access to healthcare, and provide high-quality medical devices to patients worldwide.

What is the P/E ratio of Boston Scientific 2026?

The Boston Scientific P/E ratio is 26.28.

What is the P/S ratio of Boston Scientific 2026?

The Boston Scientific P/S ratio is 6.04.

What is the Quality Investing of Boston Scientific?

The Quality Investing for Boston Scientific is 6/10.

What is the revenue of Boston Scientific 2026?

The expected Boston Scientific revenue is 22.59 B USD.

How high is the profit of Boston Scientific 2026?

The expected Boston Scientific profit is 5.19 B USD.

What is the business model of Boston Scientific

The Boston Scientific Corporation is a medical technology company that specializes in the manufacturing and development of medical devices. The company was founded in Massachusetts in 1979 and operates globally today. Its business model includes various divisions that focus on different medical specialties. The Cardiac Rhythm Management division of Boston Scientific is involved in the manufacturing of devices for the treatment of heart rhythm disorders. This includes products such as implantable defibrillators, pacemakers, and accessories. The products in this division are of high quality and have an excellent track record in treating patients with severe heart problems. The Interventional Cardiology division of Boston Scientific specializes in the manufacturing of products used in the treatment of heart diseases. This includes balloon catheters, stents, and catheter ablation systems. These products are typically minimally invasive and allow for a quick restoration of normal heart rhythm in patients. The Interventional Radiology division of Boston Scientific is focused on the manufacturing of products for the diagnosis and treatment of vascular diseases. The company produces catheters, stents, and embolization accessories, among other things. Additionally, Boston Scientific is also specialized in the development of products for the treatment of chronic pain. The products in this division include implantable pain therapy systems, neurostimulators, and accessories. These devices can alleviate patients' pain and improve their quality of life. The company is also specialized in the field of urology, including products for the treatment of conditions such as urinary incontinence and benign prostatic hyperplasia. Boston Scientific produces mesh implants and devices aimed at improving bladder control. Furthermore, the company has a division dedicated to gastrointestinal diseases, including products for the treatment of conditions like colorectal cancer and gastrointestinal bleeding. The portfolio includes endoscopes, balloon catheters, and other devices for the treatment of digestive tract disorders. Boston Scientific is committed to providing its customers with the best products. Product development is strongly focused on meeting the needs of patients and doctors. By continually developing new products, the company can expand its market position and maintain its leading position in the medical technology industry.

What is the Boston Scientific dividend?

Boston Scientific pays a dividend of 0 USD distributed over payouts per year.

How often does Boston Scientific pay dividends?

The dividend cannot currently be calculated for Boston Scientific or the company does not pay out a dividend.

What is the Boston Scientific ISIN?

The ISIN of Boston Scientific is US1011371077.

What is the Boston Scientific WKN?

The WKN of Boston Scientific is 884113.

What is the Boston Scientific ticker?

The ticker of Boston Scientific is BSX.

How much dividend does Boston Scientific pay?

Over the past 12 months, Boston Scientific paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Boston Scientific is expected to pay a dividend of 0 USD.

What is the dividend yield of Boston Scientific?

The current dividend yield of Boston Scientific is .

When does Boston Scientific pay dividends?

Boston Scientific pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Boston Scientific?

Boston Scientific paid dividends every year for the past 0 years.

What is the dividend of Boston Scientific?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Boston Scientific located?

Boston Scientific is assigned to the 'Health' sector.

Wann musste ich die Aktien von Boston Scientific kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Boston Scientific from amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on .

When did Boston Scientific pay the last dividend?

The last dividend was paid out on .

What was the dividend of Boston Scientific in the year 2025?

In the year 2025, Boston Scientific distributed 0 USD as dividends.

In which currency does Boston Scientific pay out the dividend?

The dividends of Boston Scientific are distributed in USD.

All fundamentals about Boston Scientific

Our stock analysis for Boston Scientific Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Boston Scientific Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.